Gerald R. Fink

Known for influential publications on the intricate dynamics of host-pathogen interactions, Ifat Rubin-Bejerano is a distinguished entrepreneur-scientist and currently serves as the Senior Director of Translational Research at Harvard Medical School. Her career is marked by a unique blend of scientific innovation and entrepreneurial spirit, exemplified by her co-founding of ImmuneXcite, an immunotherapy start-up. At ImmuneXcite, Ifat successfully translated foundational research into a viable commercial platform, developing a robust intellectual property strategy that underscores her visionary approach to science and business. Ifat's research expertise is deeply rooted in the study of host-pathogen interactions, particularly between fungi and immune cells. Her groundbreaking work led to the discovery of a specific fungal carbohydrate that plays a crucial role in recruiting and activating neutrophils, a type of immune cell. This discovery has significant implications for immunotherapy, as she ingeniously linked this carbohydrate to cancer-specific antibodies, thereby initiating a targeted anti-fungal immune response directed at tumors. This innovative approach has opened new avenues in the field of cancer treatment, showcasing her ability to bridge basic research with clinical applications. Her academic journey began at the Technion-Israel Institute of Technology, where she earned her B.Sc. magna cum laude, followed by a Ph.D. Her academic achievements laid a strong foundation for her subsequent research endeavors and entrepreneurial ventures. Ifat's work is characterized by a commitment to advancing scientific knowledge while simultaneously seeking practical applications that can benefit society. At Harvard Medical School, Ifat continues to lead translational research efforts, focusing on the development of novel immunotherapeutic strategies. Her role involves not only advancing scientific research but also mentoring the next generation of scientists, fostering an environment of innovation and collaboration. Her leadership in translational research is instrumental in bridging the gap between laboratory discoveries and real-world medical solutions. Ifat Rubin-Bejerano's contributions to the field of immunotherapy and host-pathogen interactions have been widely recognized, earning her a reputation as a thought leader in her domain. Her work exemplifies the potential of interdisciplinary approaches to solving complex biological challenges, and her entrepreneurial ventures highlight the importance of translating scientific discoveries into tangible benefits for patients.